Table 1.
Clinic-pathologic sample characteristics
|
No. of patients |
56 |
|---|---|
| No. of samples | 56 (100%) |
|
Median age (years) |
72 ± 10.9 |
|
Gender |
|
| Male |
33 (59%) |
| Female |
23 (41%) |
|
Location (n = 55) |
|
| Right |
16 (29%) |
| Left |
39 (71%) |
|
Grading |
|
| Well |
6 (11%) |
| Moderate |
24 (43%) |
| Poor |
26 (46%) |
|
Growth pattern |
|
| Expanding |
36 (64%) |
| Infiltrating |
20 (36%) |
|
Budding intensity |
|
| Low-grade |
40 (71%) |
| High-grade |
16 (29%) |
|
Lymph vessel infiltration |
|
| L0 |
37 (66%) |
| L1 |
19 (34%) |
|
Blood vessel infiltration |
|
| V0 |
46 (82%) |
| V1 |
10 (18%) |
|
MMR protein expression |
|
| MMR proteins expressed |
49 (87%) |
| Loss of MLH1 + PMS2 |
6 (11%) |
| Loss of PMS2 |
1 (2%) |
|
KRAS
status (n = 55) |
|
|
KRAS
wild-type |
32 (58%) |
|
KRAS
G12D |
9 (16%) |
|
KRAS
G12V |
7 (13%) |
|
KRAS
G12C |
1 (2%) |
|
KRAS
G12S |
1 (2%) |
|
KRAS
G13D |
5 (9%) |
|
BRAF
status |
|
|
BRAF
wild-type |
54 (96%) |
|
BRAF
V600E |
2 (4%) |
|
UICC Stage (n = 55) |
|
| I |
16 (29%) |
| II |
15 (27%) |
| III |
17 (31%) |
| IV | 7 (13%) |